Business Wire

Cellinfinity Bio Announces Publication and Licensing of Key Technology for Directed Evolution of Cells That Allows for More Effective Adoptive Cell Therapy

WEST HAVEN, Conn. & SAN FRANCISCO--(BUSINESS WIRE)--Cellinfinity Bio, a privately held pioneer biotechnology company developing first/best-in-class cell therapy products against solid tumors and other ...
Business Wire

bit.bio Unveils Cell Therapy Pipeline, Including Lead Candidate for Acute Liver Failure, and Significantly Expands Scientific Advisory Board with Global Experts in Cell Therapy

CAMBRIDGE, UK--(BUSINESS WIRE)--bit.bio, the company coding human cells for novel cures, today announced its cell therapy pipeline and declared its lead cell therapy candidate as it prepares to enter ...
Nasdaq

2seventy bio Presents Broad Range of New Data Highlighting Novel Approaches Across its Cell Therapies Portfolio

bbT369, a dual-targeted (CD79a/CD20) and CBLB gene edited autologous CAR T for non-Hodgkin lymphoma, showed edit-driven enhanced T cell activity in multiple preclinical models RESET, a novel TCR ...